Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, thanks for the transcript Dew. I sometimes have trouble hearing and need the transcripts to affirm what I thought I heard.
So far as some derisking - both the RSV and Covid phase 1 data at the 54:25 minute mark Luly mentioned both will be complete next Q.
EDP-325 phase 2/3 covid should start in the 2nd half.
RE: EDP 514, it almost appears that Enanta is in no hurry to partner with sub-optimal HBV compounds that stand lesser chances of success.
Gilead's HCV program succeeded due to several shrewd acts;
1) They were willing to pay more than anyone for the best nuke.
2) They partnered, then abandoned Merck'sDaclatasvir as a second combination agent (with their own in house NS5a Ledipasvir), thus retaining 100% of the HCV sales from the start.
I have to suspect that this is what Enanta would like to do with HBV. I'd guess that they are trying hard to find another/create another MOA or agent to combine EDP-514 with. That act of not partnering may show some confidence in what they have (EDP-514) and -perhaps- confidence that they can create a 2nd compound in house.
IMHO, this also rather explains also WHY the L- inhibitor in RSV.
IF Enanta can have a total lock on RSV from the get go they may reduce the enticement for others to follow in with vaccines or anti-virals.
SURE- many tried with HCV.... but how many succeeded? Still trying? Few- very few.
Time will tell if that could repeat with RSV and HBV.
Thanks Dew. Good to hear that EDP-235 will begin phase I trials this month. Plenty of room for and money to be made with a best-in-class Covid protease inhibitor.
I will feel even better when another HepB drug is chosen for trials for future combination with EDP-514.
Phase-1 for EDP-235 (qD SARS-CoV-2 protease inhibitor WITHOUT ritonavir boosting) will stat during Febuary:
https://www.sec.gov/Archives/edgar/data/0001177648/000095017022000875/enta-ex99_1.htm
ENTA FY1Q22* financials—royalty_revenue=$27.6M—12/31/21_cash=$347.7M—(down_from_$352.4M_@9/30/21):
https://www.sec.gov/Archives/edgar/data/0001177648/000095017022000875/enta-ex99_1.htm
FY1Q22 R&D expenses were $48.5M, slightly high relative to prior guidance of $150-170M for the full FY2022; FY1Q22 SG&A expenses were $9.5M, inline with prior guidance of $35-41M for full fiscal FY2022 (#msg-166871344).
--
How ENTA’s Mavyret royalty is calculated
ENTA’s royalty rate on Mavyret sales from ABBV is tiered, as shown in the table in #msg-142808661. The royalty rate is applied to the 50% Glecaprevir component of Mavyret (a 2-drug combination). The royalty tiers reset at the start of each calendar year (like tax brackets), so ENTA’s royalty rate is highest in the fourth calendar quarter (ENTA’s fiscal* Q1) and is lowest during the first calendar quarter (ENTA’s fiscal* Q2).
During calendar 4Q21 (ENTA’s FY1Q22*), ABBV sold $427M of Mavyret (#msg-167727290), noting that HCV new-patient starts were still below pre-pandemic levels. ABBV issued calendar-2022 guidance for Mavyret sales of $1.7B, unchanged from the calendar-2021 number (#msg-167728327).
*ENTA’s fiscal year ends on September 30.
As it pertains to Enants's Covid program
https://www.marketwatch.com/story/shionogi-aims-to-begin-global-phase-3-trial-of-covid-19-pill-late-february-271643611039
"Currently, Shionogi is conducting what it calls a Phase 2b/3 trial in Japan and some other countries but not in the U.S. That trial is expected to end by late July this year, it said. Separately, it said it is talking to the Food and Drug Administration and the European Medicines Agency about a global Phase 3 trial that it targets to begin in late February."
---------
It appears that Shionogi's covid program entered phase 1 the end of July- 6 months ago. Which may help gauge the speed of Entanta's program.
As the Pfizer covid antiviral will be first to market it should see huge demand, but it will not likely be best in class and could soon yield to an unboosted antiviral- such as Shionogi's.
As recently as 3 weeks ago at the JP Morgan healthcare conference J Luly reiterated that there will be a shortage of covid antiviral product and that Enanta could have potentially a best in class protease inhibitor.
Enanta's drug will commence Phase 1 clinic in Febuary 2022.
What I'm kicking around is the trajectory of covid, the possible extended use of EUA which could greatly benefit ENTA, and the failures or weaknesses of Enanta's covid competitors. (MRK, AVIR, PRDS?--maybe ultimately PFE)
IF both Enanta and Shionogi did well with their covid theraputic protease inhibitors it's hard to see Paxlovid being a long term preferred med.
The question is how effective will they be? Will one be better? How quickly can they get US/EU approval?
It seems that the worst case covid investing scenario for Enanta would have been a short pandemic- like traditional influenza.
But instead the reverse happened; Alpha, then Delta, now Omicron, and there may be more resistant variants on the way.
There is still a lot of vaccine hesitancy. It seems obvious that a sizeable un-vaccinated (or under boosted) pool will remain and face both the current covid and future resistant strains. A prolonged pandemic with elusive cures may encourage the continued use of EUA.
Equally interesting as it pertains to VIR you can see that support can quickly be withdrawn. Can they scale up quick enough if the target keeps shifting? The antivirals look good there.
RE: HBV Enanta hasn't rushed into other collaborations. It makes me think that they prefer in-house. There truly may not be much out there worthy of a collaboration. Enanta can carefully tailor two Enanta compounds to work together instead of bolting together random parts available thru collaboration.
--Although the RNA destabilzer didn't work out they still may have some worthwhile data that helps with the next compound. Enanta has combined 514 with a nuke so they must have an idea of what they need for the next piece. I'm not sure the competition has that.
A large number of biotech stocks are at or close to their 52 week lows now. I bought a small amount of several today including ABBV, ENTA, SGEN,IMGN and even CDMO. I was toying with opening a position in VIR as their monoclonal antibody is the only one that works with omicron and they are now scaling up production. One caveat is their HepB program doesn't look stellar to me but that is down the road.
LOL: Idenix. That's one I hadn't heard in a longer while. : )
IF I had thought there was potential for Zepatier level success I might have tripled my SMALL position.
Meanwhile I'm out 10-20 bucks for being impetuous.
Zepatier—that's a name I hadn't heard in a while, LOL.
I purchased a small amount a few weeks ago to force my attention- which worked.
I had thought; well, what if it became a Zepatier?
But the more I investigated the less attractive it looked. That ended yesterday when I sold.
It was never just one thing, but a number of things- and that disquieting number only grew.
ENTA’s insiders cumulatively own a 12.4% equity stake:
https://www.sec.gov/Archives/edgar/data/0001177648/000156459022001953/enta-def14a_20220303.htm#BENEFICIAL_OWNERSHIP_COMMON_STOCK
More from PRDS S-1 filing (p.97):
That's a reasonable inference. PBI-0451 may need ritonavir boosting to enable qD dosing.
PRDS phase-1a is investigating ritonavir boosting:
#msg-167618930
I cannot comment on that with any knowledge or authority.
Years back when I was in a Gilead trial I was curious where the drug batches came from for trials. I'm in Iowa, and as it happened it seemed that one location may have been my hometown.
I think there may be a difference between the early trials and small batches and the large scale final formulations. Recall that in NASH Enanta shifted I think from a liquid to pill form which changed the bio-availability.
I think both Enanta and Pardes maintained they had adequate funding (and I think adequate supply) until such a time as large amounts of drug (and I'd suppose some registered/validated process of mass production) was required. I'm absolutely out of my depth here. : )
I also wonder if the EUA amount of drug required, let's say for a phase 2 is less than a standard amount for a full blown standard phase 2. It seemed to me that in vaccines one of the criticisms was that the FDA was proceeding with scant data -based upon trial participant cohort size.
Finally, the trial I was in I was in a 24 week once a day 200mg dose. (if I correctly recall)
In the case of Enanta it could be once a day between 100 to 500mg for 5 days. That's a large difference in quantity required.
What takes a lot of time is generating enough API for high-volume output. Producing small amounts of the drug for early-stage clinical trials is not a problem.
[OT]—Registering for Twitter is free. Moreover, I never see any ads (a/k/a promoted tweets), and this can't be due to my having an browser-based ad-blocker (which wouldn't be able to recognize promoted tweets as ads). I access Twitter using the website; maybe things are different for those who access Twitter via mobile platforms.
I don't know, but possibly.... just as paywalls have become more stringent I think twitter has tightened up content provided as a means to lever the unregistered.
I used to be able to view months, perhaps years.
Over time, but today particularly by clicking on your link a few posts back I could view 3 tweets of yours.
By clicking on your profile I am able to view 4 (the Pharmasett tweet being one)
By viewing $ENTA daily I am likely able to read yours as they arrive.
I suppose I should register or pay. Probably true also-subscribe to Ihub. : )
I didn't realize there were restrictions on what a non-subscriber could read.
Yes. I read as much as I'm allowed to as an unregistered twitter lurker. I suppose I should register/join. I think in the past I could view more. It's a great resource. : )
Good points. Did you read the other tweets in the thread I linked to?
The article was primarily about Pardes which doesn't look that promising to me -albeit possibly better than Pfizer. In a recent pitch they mentioned that they were going to have to run more phase 1 in the USA, and the once a day dosing without boosting seemed a bit more tentative.
Further, a follow on compound so close to their lead covid program seems to suggest a rushed entry.
The very last line in the article stated the Pardes compound *could* be approved at the very earliest by year end. That seemed like a stretch.
Shionogi seems far more promising. (I've seen no response data tho)
The covid landscape keeps changing. There always seems to be a new resistant variant to vaccines. The seriousness of covid to the unvaxxed remains, and may take a while before it visits both the unvaxxed and the less protected or immunocompromised/ aged/ groups plagued by other co-morbidities and diminishing vaccine protection. (4th shot boosters not very effective?)
On the other hand the focus on the main players in antivirals will become more clear - as will the treatment tail of covid. Will it become like the swine flu and depart, or will it become something more like a continual almost endemic- leaving far more slowly than we first expected?
Much like early HCV programs, the initial players success may be short lived. Pfizer's Paxlovid seems the main player. The Merck compound molnupiravir seems far less important.
The Pardes covid presentations might be better than their lead compound. : )
Jay Luly exercised and held $600K of stock on 1/15/21:
https://www.sec.gov/Archives/edgar/data/0001177648/000106299322001104/xslF345X03/form4.xml
Exercising and holding—paying the withholding tax with cash rather than forfeited shares—is mathematically equivalent to an open-mkt purchase.
Even IF it was so that the Leerink price of $80.00 is correct....
we are still 20 dollars under that.
I feel as though once the covid molecule EDP-325 moves along and is de-risked the share price will move.
If ONLY the covid program is good- just that one thing will surely move us upward- well beyond $80.00/share.
Willow,
We are on the same wavelength as I bought more yesterday and bought again today.
Enanta is thinly traded. So it doesn't take much trading to move the needle.
There was ONE downgrade of 5 dollars and it fell over $10 in two days. A downgrade might do that. A retiring board member selling shares adds fuel and velocity to the selling..... triggering yet more selling.
What will the stock trade at when they start covid clinic work in a few weeks?
When they post (and if) positive RSV data soon?
When (and if) they start covid phase 2/3 in second half of year?
I bought more today.
Why the plunge today on a $5 price target drop?
Correct—the "second" MoA is an off-patent nuc.
The main differences between the 1/11/22 slide set and the previous (11/18/21) slide set are in slide #15 (EDP-323 info) and #30 (2022 news flow).
Shionogi—(SGIOY)—is a Japanese Big Pharma—certainly not under-the-radar. I mentioned Shionogi’s COVID program in #msg-167153263; the program is in phase-2/3 in Asia, but hasn’t yet started in the US.
As you know I bought a small amount of Pardes (at this moment green)- not so much as a hedge, but as a sort of surrogate real time notification system, and to force myself to pay more attention to the competition.
One could do the same with other covid compounds being developed.
When I look at Enanta's slide 20 (2022) I see another competitor with a PI. They are in phase 2/3 and project once a day dosing.
It is even more thinly traded than ENTA and in spite of possibly being a contender their stock has been flat- perhaps the opposite of AVIR in a few ways. SGIOY (?). It seems wholly off the radar. All things being the same- approval before Pardes.
If PFE will have the major covid antiviral- whose will unseat PFE's?
Any thoughts?
One unknown in this, which I expect that no one knows the answers, are two factors (perhaps this would be better as a separate post)
1) The trajectory of covid which could mutate into another delta like scenario which escapes vaccines OR conversely promptly winds down to endemic
2) The path of EUA (Emergency Use Authorization) and it's effects upon drugs in development. The outcomes for drugs being developed could change radically (along with their stock price) contingent upon -for example purposes only- if the EUA extended into next year versus if it ended next month.
I'm forced to imagine how the EUA will impact drugs in development- both in best and worst case scenarios.
The difference is timing is so small I consider it insignificant.
It was ALGS' lead HBV candidate, which is why the stock was down >50% yesterday.
This is yesterday's ALGS PR:
https://finance.yahoo.com/news/aligos-halting-further-development-stops-130000126.html
*Correction* “Hep B asset”
(ENTA)-ALGS drops Hep B program.
from: @OxAnalyst on Twitter
$ALGS dropping STOPS hep B asset* due to lack of efficacy (no meaningful HBsAg reduction)
— . (@CrocsAnalyst) January 6, 2022
one of two clinical candidates in their pipeline pic.twitter.com/IqC5poNCwM
ENTA 2022 newsflow:
https://www.enanta.com/investors/news-releases/press-release/2022/Enanta-Pharmaceuticals-to-Provide-Updates-on-its-Research-and-Development-Programs-and-Outlook-for-2022-at-the-40th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx
• EDP-235 phase-1 starting Feb 2022. (EDP-235 is a SARS-CoV-2 protease inhibitor.)
• Phase-2 ‘RSVP’ data for EDP-938 in 2Q22.
• EDP-323 (RSV L-protein inhibitor) phase-1 starting 2H22.
CEO, Jay Luly is a 6.5% shareholder:
https://www.sec.gov/Archives/edgar/data/0001177648/000119312521361165/d273825dsc13da.htm
Followers
|
98
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3312
|
Created
|
03/20/13
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |